Management of Post‑Lung Transplant Patients with Vaginal Bleeding and Endometrial Thickening

Diagnostic Priorities

Obtain endometrial tissue (biopsy or dilation & curettage) immediately to exclude endometrial cancer in any transplant recipient with abnormal uterine bleeding and thickened endometrium. The American Society of Transplantation emphasizes that tissue diagnosis is non‑negotiable because immunosuppressed patients have a markedly increased malignancy risk. 1
Perform transvaginal ultrasound (TVUS) as the first‑line imaging modality to assess endometrial thickness and detect structural lesions. This recommendation follows radiology best‑practice guidelines. 3
If TVUS is limited by body habitus or uterine pathology, proceed directly to pelvic MRI with diffusion‑weighted imaging (DWI) to evaluate for endometrial cancer, polyps, or hyperplasia. MRI provides superior tissue characterization and can differentiate benign from malignant pathology even in the presence of confounding factors. 3
Never delay tissue sampling while awaiting additional imaging; histologic confirmation must precede therapeutic decisions. 3

Solid‑organ transplant recipients exhibit elevated standardized incidence ratios for gynecologic cancers, including endometrial carcinoma, compared with the general population. The increased risk is driven by chronic immunosuppression and viral oncogenesis. 1
Azathioprine use is linked to a higher incidence of certain gynecologic malignancies, particularly those related to human papillomavirus (HPV). Registry data support this association. 2
Calcineurin inhibitors (e.g., tacrolimus) show a dose‑dependent relationship with secondary malignancies. Observational studies demonstrate this trend. 1
Chronic corticosteroid therapy raises the risk of metabolic complications (hyperglycemia, diabetes), which are independent risk factors for type 1 endometrial cancer. 1
Traditional endometrial‑cancer risk factors remain relevant in transplant patients: obesity, diabetes mellitus, nulliparity, early menarche or late menopause, and unopposed estrogen exposure. 1
The median age of endometrial‑cancer diagnosis in the general population is 60 years, but immunosuppression may shift this risk profile. 1

Endometrial polyps are a common structural cause of abnormal bleeding in transplant recipients. 1
Endometrial hyperplasia, a recognized precursor to type 1 endometrial carcinoma, must be considered. 1
Chronic steroid exposure can induce endometrial changes that mimic pathology. Evidence from hepatology literature describes this medication‑related effect. 7

Mandatory gynecologic‑oncology consultation before any intervention to ensure cancer‑specific expertise in the immunosuppressed host. 2
Involvement of transplant pulmonology is required for any modification of the immunosuppressive regimen, balancing oncologic treatment against graft‑rejection risk. 2

Consider switching azathioprine to mycophenolate mofetil (MMF); MMF has been associated with lower post‑transplant cancer rates due to its activity against inosine monophosphate dehydrogenase expressed in solid tumors. 1
Evaluate conversion to an mTOR inhibitor (e.g., sirolimus), which has demonstrated activity against gynecologic malignancies, including recurrent uterine cancer (adjusted hazard ratio ≈ 0.60 for malignancy reduction). 1
Decisions regarding immunosuppression reduction or withdrawal must be individualized through multidisciplinary discussion, taking into account graft function, rejection history, cancer stage, and therapeutic goals. 2

Do not attribute vaginal bleeding solely to immunosuppressive medications without first excluding malignancy. 1
Avoid unilateral immunosuppression changes without transplant‑team input, as this may precipitate acute rejection. 2
Standard cancer‑treatment protocols should be adapted for transplant recipients; unmodified regimens may be unsafe. 2